
CLAIMS

1. A solid pharmaceutical composition, comprising a compound of formula **I**, a diluent, a binder, a disintegrant, and a lubricant,



I

wherein

the diluent is selected from the group consisting of microcrystalline cellulose, mannitol, lactose, pregelatinized starch, and a mixture thereof;

the disintegrant is selected from the group consisting of sodium carboxymethyl starch, croscarmellose sodium, and a mixture thereof;

the binder is selected from the group consisting of hydroxypropyl methylcellulose, carboxymethylcellulose, carboxymethylcellulose sodium, ethylcellulose, methylcellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, polyvinylpyrrolidone, and a mixture thereof;

the lubricant is selected from the group consisting of magnesium stearate, colloidal silicon dioxide, sodium dodecyl sulfate, and a mixture thereof;

the solid pharmaceutical composition is prepared by a direct compression method.

2. The solid pharmaceutical composition according to claim 1, wherein,

the solid pharmaceutical composition is a pharmaceutical composition in unit dose, and the mass of the compound of formula **I** in the composition per unit dose is 0.01 mg-10 mg; or

the amount of the compound of formula **I** is selected from 0.01%-10% wt.

3. The solid pharmaceutical composition according to claim 1, wherein,

the diluent is selected from the group consisting of microcrystalline cellulose, pregelatinized starch, and a mixture thereof.

4. The solid pharmaceutical composition according to claim 1, wherein,

the amount of the diluent is selected from 50% wt or more.

5. The solid pharmaceutical composition according to claim 4, wherein,

the diluent comprises microcrystalline cellulose, and the amount of the microcrystalline cellulose is selected from 30%-90% wt; or
the diluent comprises pregelatinized starch, and the amount of the pregelatinized starch is selected from 5%-35% wt; or
the diluent is microcrystalline cellulose and pregelatinized starch; preferably, 30%-90% wt of microcrystalline cellulose and 5%-35% wt of pregelatinized starch, and the amount of the diluent is 50% wt or more.

6. The solid pharmaceutical composition according to claim 1, wherein,
the disintegrant is sodium carboxymethyl starch.

7. The solid pharmaceutical composition according to claim 6, wherein,
the amount of the disintegrant is selected from 1.0%-7.0% wt; or
the disintegrant is sodium carboxymethyl starch, and the amount of the sodium carboxymethyl starch is selected from 1.0%-7.0% wt.

8. The solid pharmaceutical composition according to claim 1, wherein,
the binder is hydroxypropyl methylcellulose.

9. The solid pharmaceutical composition according to claim 8, wherein,
the amount of the binder is selected from 0.1%-5% wt; or
the binder is hydroxypropyl methylcellulose, and the amount of the hydroxypropyl methylcellulose is selected from 0.1%-5% wt.

10. The solid pharmaceutical composition according to claim 1, wherein,
the lubricant is selected from the group consisting of magnesium stearate, colloidal silicon dioxide, and a mixture thereof.

11. The solid pharmaceutical composition according to claim 10, wherein,
the amount of the lubricant is selected from 0.1%-5% wt; or
the lubricant comprises colloidal silicon dioxide, and the amount of the colloidal silicon dioxide is selected from 0.05%-3.0% wt; or
the lubricant comprises magnesium stearate, and the amount of the magnesium stearate is selected from 0.05%-3.0% wt; or

the lubricant is selected from the group consisting of colloidal silicon dioxide and magnesium stearate; preferably, 0.05%-3.0% wt of colloidal silicon dioxide and 0.05%-3.0% wt of magnesium stearate, and the amount of the lubricant is selected from 0.1%-5% wt.

12. The solid pharmaceutical composition according to any one of claims 1-11, wherein the solid pharmaceutical composition comprises:
0.02%-8.0% wt of the compound of formula **I**;
50% wt or more of microcrystalline cellulose, mannitol, lactose, pregelatinized starch, or a mixture thereof;
1.0%-7.0% wt of sodium carboxymethyl starch, croscarmellose sodium, or a mixture thereof;
0.1%-5% wt of hydroxypropyl methylcellulose, carboxymethylcellulose, carboxymethylcellulose sodium, ethylcellulose, methylcellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, polyvinylpyrrolidone, or a mixture thereof; and
0.1%-5% wt of magnesium stearate, colloidal silicon dioxide, sodium dodecyl sulfate, or a mixture thereof.

13. The solid pharmaceutical composition according to any one of claims 1-12, wherein the solid pharmaceutical composition has at least one of the following characteristics:
the bulk density is less than or equal to 0.50 g/mL, preferably, 0.30 g/mL-0.50 g/mL;
the tap density is less than or equal to 0.65 g/mL, preferably, 0.50 g/mL-0.65 g/mL;
the Hausner ratio is 1.31-1.40;
particles, with an amount of more than or equal to 50%, preferably, 50%-80%, have a size of less than 75 μm.

14. The solid pharmaceutical composition according to any one of claims 1-13, wherein,
the dosage form of the solid pharmaceutical composition may be selected from a powder, a granule, a tablet, a capsule, a pill, a pellet, a dispersion and an inhalable powder, preferably, a tablet.

15. A method for preparing the solid pharmaceutical composition of the compound of formula **I** according to any one of claims 1-14, comprising the direct compression method.

16. A method for preparing the solid pharmaceutical composition of the compound of formula **I** according to any one of claims 1-14, comprising:

1) mixing the compound of formula I with part or all of the diluent and, optionally present, at least one of the binder, the disintegrant and the lubricant;
2) mixing the resulting mixture obtained in step 1) with the rest of the diluent and at least one of the rest of the binder, the disintegrant and the lubricant;
optionally, 3) mixing the resulting mixture obtained in step 2) with the rest of the excipients; and
4) tableting the resulting mixture obtained in step 2) or step 3).

17. The method according to claim 15 or 16, wherein,
the method comprises the following steps: 1) preparing the compound of formula **I**, the diluent, the disintegrant, the binder and the lubricant into a mixture; and 2) tableting.

18. The method according to any one of claims 15-17, wherein,
the mixture comprising the compound of formula I and the diluent is not subjected to milling.

19. Use of the solid pharmaceutical composition of the compound of formula **I** according to any one of claims 1-14 for the manufacture of a medicament for the treatment or prevention of a disease associated with TLR7.

20. The use according to claim 19, wherein the disease associated with TLR7 is selected from a viral infectious disease; more preferably, the viral infectious disease is selected from the group consisting of hepatitis B and hepatitis C.